Broad Institute to appeal CRISPR patent revocation

The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office (EPO) to revoke one of its patents covering CRISPR/Cas9 technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

Biotechnology

EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing

4 November 2019 The Board of Appeal of the European Patent Office has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.

Americas

USPTO rules Broad owns CRISPR animal cell editing patents

1 March 2022 Patents core to the breakthrough gene-editing technology CRISPR belong to the University of Harvard and the Massachusetts Institute of Technology’s Broad Institute, the US Patent and Trademark Office has ruled.